Kura Oncology AI Stock Analysis
Want to see KURA full AI Analyst Report?
Kura Oncology (KURA) AI Stock Analysis
Kura Oncology
(NASDAQ:KURA)
The score is held down primarily by weak financial performance (large ongoing losses, equity erosion and renewed cash burn) and bearish technicals (downtrend and negative momentum). A notably positive earnings call—highlighting strong commercial execution, pipeline progress, and improved funding visibility—partially offsets these risks, while valuation provides limited support due to negative earnings and no dividend.
Kura Oncology (KURA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $713.90M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.14M
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 1.55
- Revenue Growth
- -23.76%
- EPS Growth
- -33.09%
- Country
- US
- Employees
- 260
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Kura Oncology Business Overview & Revenue Model
Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...
Kura Oncology Earnings Call Summary
The call was strongly positive, driven by 53% sequential COMZIFTI revenue growth, 30% growth in new patient starts, expanding prescribing accounts, majority market share, substantial ASH data visibility, progress toward frontline registration, FDA alignment for a darlafarnib registrational study, and a strengthened funding position. The principal negatives were lower collaboration revenue, immature duration data, ongoing competition, and the fact that just under half of the incident NPM1 population is receiving menin inhibitor therapy. Management presented these items as manageable opportunities or execution priorities rather than material setbacks.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects collaboration revenue of $40 million to $45 million for 2020 and is maintaining guidance of $90 million to $110 million in each of 2027 and 2028; September 30th cash resources, subsequent financing proceeds, and approximately $180 million in anticipated Kyowa Kirin payments are expected to support the current operating plan beyond the initial Ziftomenib top line results expected in 2028. The first top line results from the intensive chemotherapy trial in KOMET-017 are expected in 2028, while Kura plans to submit an IND by the end of this year and initiate an approximately 40-patient darlafarnib monotherapy study in the first half of 27, complete RCC enrollment in the first half of 27 and report initial data in the second half, and dose the first PDAC patient in the first half of 27 with the potential for preliminary data in the second half. The company continues to guide to the approximately 6 months duration of treatment and described 5 to 6 months as steady state.
Kura Oncology Financial Statement Overview
Summary
Revenue is scaling and reported gross margins are very high, but profitability remains deeply negative (large operating and net losses). Balance-sheet risk is elevated due to sharp equity erosion and higher debt-to-equity, and cash flow has turned meaningfully negative again with volatile burn.
Income Statement
38NegativeBalance Sheet
34NegativeCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.31M | 67.48M | 53.88M | 0 | 0 | 0 |
| Gross Profit | 78.08M | 67.42M | 53.88M | -849.00K | 0 | 0 |
| EBITDA | -290.29M | -275.82M | -169.50M | -150.23M | -134.85M | -129.49M |
| Net Income | -292.87M | -278.67M | -173.98M | -152.63M | -135.84M | -130.47M |
Balance Sheet | ||||||
| Total Assets | 566.50M | 738.36M | 760.16M | 448.94M | 456.31M | 534.05M |
| Cash, Cash Equivalents and Short-Term Investments | 492.10M | 667.24M | 727.39M | 423.96M | 437.99M | 517.96M |
| Total Debt | 25.83M | 20.46M | 16.59M | 17.20M | 14.02M | 6.88M |
| Total Liabilities | 548.54M | 564.23M | 346.52M | 51.66M | 36.03M | 27.44M |
| Stockholders Equity | 17.96M | 174.13M | 413.64M | 397.27M | 420.28M | 506.61M |
Cash Flow | ||||||
| Free Cash Flow | -89.12M | -70.70M | 133.84M | -124.99M | -110.69M | -105.70M |
| Operating Cash Flow | -85.57M | -64.06M | 134.32M | -124.82M | -110.06M | -104.55M |
| Investing Cash Flow | 12.98M | -13.10M | -101.59M | 15.56M | 32.63M | -126.83M |
| Financing Cash Flow | 35.25M | 1.79M | 154.42M | 94.78M | 38.56M | -3.44M |
Kura Oncology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KURA, the sentiment is Negative. The current price of 7.77 is below the 20-day moving average (MA) of 8.96, below the 50-day MA of 10.17, and below the 200-day MA of 9.77, indicating a bearish trend. The MACD of -0.79 indicates Positive momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 24.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KURA.
Kura Oncology Risk Analysis
Kura Oncology disclosed 75 risk factors in its most recent earnings report. Kura Oncology reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksKura Oncology Peers Comparison
Overall Rating
GERN51Neutral
CTMX47Neutral
KURA46Neutral
ORIC44Neutral
ZNTL44Neutral
PRLD38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $622.98M | -13.79 | -22.27% | ― | 18.60% | 37.60% | |
| 47Neutral | $444.73M | -4.52 | -33.97% | ― | -87.66% | -210.45% | |
| 46Neutral | $713.90M | -2.35 | -336.24% | ― | -23.76% | -33.09% | |
| 44Neutral | $814.71M | -5.82 | -35.35% | ― | ― | 28.64% | |
| 44Neutral | $167.05M | -0.89 | -75.82% | ― | -100.00% | 7.45% | |
| 38Underperform | $275.32M | -4.37 | -75.35% | ― | 220.34% | 55.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KURA | Kura Oncology | 7.77 | -3.08 | -28.39% | |
| GERN | Geron Corporation | 0.97 | -0.16 | -14.42% | |
| CTMX | CytomX Therapeutics Inc. | 2.04 | -1.51 | -42.54% | |
| ZNTL | Zentalis Pharmaceuticals Inc | 1.70 | 0.38 | 28.79% | |
| ORIC | Oric Pharmaceuticals Inc | 7.86 | -4.20 | -34.83% | |
| PRLD | Prelude Therapeutics, Inc. | 3.45 | 1.80 | 109.09% |
Kura Oncology Corporate Events
Kura Oncology Establishes Caspian Partnership for Cardiometabolic Focus
PositiveOn September 8, 2026, Caspian Therapeutics completed a $50.0 million Series A preferred stock financing, in which Kura Oncology invested $4.3 million, leaving Kura with approximately 49.2% of Caspian’s outstanding capital stock. The transaction bring...
Kura Oncology Appoints Jennifer Fulk as New CFO
PositiveEffective September 8, 2026, Kura Oncology appointed industry veteran Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer, replacing Troy E. Wilson and Thomas Doyle in those specific roles. Fulk brin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026
